How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

101,779 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study. Full Text available with Trip Pro

Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study. We tried to clarify, by using representative national data in a real-world setting, whether single-pill combinations (SPCs) of antihypertensives actually improve medication adherence.A nationwide population-based study.We used a 2.2% cohort (n=1 048 061) of the total population (n=46 605 433) that was randomly extracted by National Health Insurance of Korea from 2008 to 2013 (...) .We included patients (n=116 677) who were prescribed with the same antihypertensive drugs for at least 1 year and divided them into groups of angiotensin II receptor blocker (ARB)-only, calcium channel blocker (CCB)-only, multiple-pill combinations (MPCs) and SPCs of ARB/CCB.Medication possession ratio (MPR), a frequently used indirect measurement method of medication adherence.Adjusted MPR was higher in combination therapy (89.7% in SPC, 87.2% in MPC) than monotherapy (81.6% in ARB, 79.7% in CCB

2019 BMJ open

122. Risk assessment of patient factors and medications for drug-related problems from a prospective longitudinal study of newborns admitted to a neonatal intensive care unit in Brazil. Full Text available with Trip Pro

Risk assessment of patient factors and medications for drug-related problems from a prospective longitudinal study of newborns admitted to a neonatal intensive care unit in Brazil. To identify patient factors and medications associated with the occurrence of drug-related problems (DRPs) in neonates admitted to neonatal intensive care units (NICUs).Prospective, longitudinal study.NICU of a teaching hospital in Brazil.Data were collected from the records of the clinical pharmacy service of all (...) ), amikacin (AOR 1.82) and omeprazole (AOR 1.66). These medicines represented one-third of all prescribed drugs.Gestational age, 5 min Apgar <7, and neurological, cardiac and renal diseases are risk factors for DRP in NICUs. Alprostadil, omeprazole and several anti-infectives were associated with greater risk of DRP.© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

2019 BMJ open

123. How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoid arthritis or inflammatory bowel disease?

How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoid arthritis or inflammatory bowel disease? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives (...) for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 27, 2019 It’s all in the details... or is it? Biosimilars versus biologics for inflammatory conditions. Clinical Question: How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoid arthritis or inflammatory bowel disease? Bottom Line: For patients with rheumatoid arthritis, other inflammatory

2019 Tools for Practice

124. Pharmaceutical Representative

Representative Pharmaceutical Representative Aka: Pharmaceutical Representative , Drug Rep , Prescribing Cost , Sunshine Act From Related Chapters II. Research: Studies Evaluation of 446 physicians surveyed Higher Prescribing Cost risks Pharmaceutical Representative exposure Group practice setting References Direct drug advertising to healthcare consumers Appears to increase sale of drugs May result in inappropriate prescribing practices Pharmaceutical samples raise overall Prescribing Costs Poorest patients (...) are the least likely to receive free drug samples Typical drug sample recipient has health insurance and lives far above poverty line >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004) III. Precautions: Gifts Sunshine Act (U.S. regulation as of August 2013) Pharmaceutical Representative gifts over $10 are reported to a public list (with the provider's name) IV. Resources No Free Lunch V. References Images: Related links to external sites (from Bing) These images

2018 FP Notebook

125. Pharmaceutical Representatives

Representatives Pharmaceutical Representatives Aka: Pharmaceutical Representatives , Drug Rep , Prescribing Cost , Sunshine Act From Related Chapters II. Research: Studies Evaluation of 446 physicians surveyed Higher Prescribing Cost risks Pharmaceutical representative exposure Group practice setting References Direct drug advertising to healthcare consumers Appears to increase sale of drugs May result in appropriate prescribing practices Pharmaceutical samples raise overall Prescribing Costs Poorest patients (...) are the least likely to receive free drug samples Typical drug sample recipient has health insurance and lives far above poverty line >25% ($16 billion) of drug company advertising ($57 billion) was spent on samples (2004) III. Precautions: Gifts Sunshine Act (U.S. regulation as of August 2013) Pharmaceutical representative gifts over $10 are reported to a public list (with the provider's name) IV. Resources No Free Lunch V. References Images: Related links to external sites (from Bing) These images

2018 FP Notebook

126. Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults

technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McDonagh M, Peterson K, Thakurta S. Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults. Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2010 Authors' conclusions For the maximal patient outcome of total control (no emesis, no use of rescue medication (...) Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults McDonagh M, Peterson K, Thakurta S Record Status This is a bibliographic record of a published health

2010 Health Technology Assessment (HTA) Database.

127. Responsible use of high-risk medical devices: the example of 3D printed medical devices

AIMDD Active Implantable medical device Directive ATMP BCIP BOIP BFM advanced therapy medicinal product Benelux Convention on Intellectual Property Benelux Office for intellectual property Budget of Financial Means CAD computer-aided design CBA cost-benefit analyses CC Civil Code CCA cost-consequence analyses CEA CI cost-effectiveness analyses confidence interval CMA cost-minimization analyses CPD CRD College physicians-directors Centre for Review and Dissemination CUA cost-utility analyses CPC (...) EUDAMED European Databank on Medical Devices EUIPO EUnetHTA European Union Intellectual Property Office European Network for Health Technology Assessment EUTM DD DMCA FAMHP European Union Trade Mark Directive on the legal protection of designs Digital Millennium Copyright Act Federal Agency for Medicines and Health Products (FAGG-AFMPS) FDA Food and Drug Administration GDPR General Data Protection Regulation HSR HTA Health Services Research Health Technology Assessment IC IDEAL INAHTA Insurance

2018 Belgian Health Care Knowledge Centre

128. The cost-effective, but forgotten, medical endometriosis therapy: a prospective, quasi-randomized study on progestin therapy. (Abstract)

The cost-effective, but forgotten, medical endometriosis therapy: a prospective, quasi-randomized study on progestin therapy. Endometriosis represents nowadays a real burden for the patients as well as for the physicians, as it requires surgical and/or medical treatment, often long - termed and repeated. Moreover, the high costs necessary to diagnose and treat endometriosis represent a real economic burden, being comparable to other chronic diseases like diabetes or rheumatoid arthritis (...) . Therefore, the physicians dealing with this disease should take into account not only the efficacy of the treatment, but also the economic aspects and patients compliance. The present paper analyses the efficiency of progestins (lynestrenol and medrogestone) in endometriosis as a cost - effective, but forgotten medical therapy of the disease. Our study underlines the good tolerability of progestins, as they have limited side effects, the compliance of patients being high. They are also low-cost

2018 Facts, views & vision in ObGyn Controlled trial quality: uncertain

129. Prevalence, clinical relevance and predictive factors of medication discrepancies revealed by medication reconciliation at hospital admission: prospective study in a Swiss internal medicine ward. Full Text available with Trip Pro

Prevalence, clinical relevance and predictive factors of medication discrepancies revealed by medication reconciliation at hospital admission: prospective study in a Swiss internal medicine ward. Medication reconciliation (MedRec) is a relevant safety procedure in medication management at transitions of care. The aim of this study was to evaluate the impact of MedRec, including a best possible medication history (BPMH) compared with a standard medication history in patients admitted (...) to an internal medicine ward.Prospective interventional study. Data were analysed using descriptive statistics followed by univariate and multivariate Poisson regression models and a zero-inflated Poisson regression model.Internal medicine ward in a secondary care hospital in Southern Switzerland.The first 100 consecutive patients admitted in an internal medicine ward.Medication discrepancies between the medication list obtained by the physician and that obtained by a pharmacist according to a systematic

2019 BMJ open

130. Access to medicines: relations with the institutionalization of pharmaceutical services Full Text available with Trip Pro

, exploratory, and evaluative study composed of an information survey in a representative sample of cities, stratified by Brazilian regions. Access was defined based on the acquisition of medicines reported by the patient, ranging between: total, partial, or null. The institutionalization of pharmaceutical services was analyzed based on information provided by pharmaceutical services providers and by those responsible for medicines delivery. Chi-square test and multinomial logistic regression were used (...) Access to medicines: relations with the institutionalization of pharmaceutical services To analyze the relationship between access to medicines by the population and the institutionalization of pharmaceutical services in Brazilian primary health care.This study is part of the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos - Serviços 2015 (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines - Services 2015), a cross-sectional

2017 Revista de saúde pública

131. Postgraduate Courses in Pharmaceutical Medicine in Italy Full Text available with Trip Pro

in pharma companies or in contract research organizations: several Italian universities are offering high quality courses, and in the last 10 years, more than 1,200 professionals received a postgraduate education in pharmaceutical medicine. This result places Italy on top of countries concerned about the professional education of people involved in drug development and will represent an asset for a larger involvement of Italian clinical sites in the global process of clinical research. (...) Postgraduate Courses in Pharmaceutical Medicine in Italy Italy has a significant tradition of excellence in the area of clinical trials (CTRs): important achievements in the clinical development of rifampicin and adriamycin, the two most famous drugs discovered in the research laboratories of two Italian pharmaceutical companies, paved the way to the establishment of a culture of clinical development, mainly in the areas of antimicrobials and oncology. Despite the fact that now the Italian

2017 Frontiers in medicine

132. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response

COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response NICE guideline Published: 9 April 2020 www.nice.org.uk/guidance/ng169 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 13Contents Contents Overview 4 1 Communicating with patients and minimising risk 5 2 Supplying medicines 7 3 Patients not known to have COVID-19 8 Treatment considerations 8 4 Patients known or suspected to have COVID-19 10 T opical treatment 10 Systemic treatment 10 5 Modifications to usual care 12 6 Healthcare workers 13 COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169) © NICE 2020

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

133. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response

or hepatology team first • that they can continue taking aminosalicylates, and that these drugs do not affect the immune response • to write down a list of the medicines they take and any conditions they have, to give to healthcare staff if they need to seek treatment for COVID-19 • that if they have been advised to self-isolate they should follow the UK government stay at home advice for households with possible coronavirus infection. 1.5 Minimise face-to-face contact by: COVID-19 rapid guideline (...) and medicines, for example, pharmacy deliveries, postal services, NHS Volunteer Responders or introducing drive-through pick-up points for medicines • extending intervals between drug monitoring (see recommendation 2.8 in the section on treatment considerations) and using local services for blood tests if possible. 1.6 If patients need to attend face-to-face appointments, ask them to help reduce the risk of contracting or spreading COVID-19 by: • coming to the appointment alone • having only 1 parent

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

134. Choosing emergency medicine: Influences on medical students' choice of emergency medicine. Full Text available with Trip Pro

Choosing emergency medicine: Influences on medical students' choice of emergency medicine. Relatively little is understood about which factors influence students' choice of specialty and when learners ultimately make this decision.The objective is to understand how experiences of medical students relate to the timing of selection of Emergency Medicine (EM) as a specialty. Of specific interest were factors such as how earlier and more positive specialty exposure may impact the decision-making (...) process of medical students.A cross-sectional survey study of EM bound 4th year US medical students (MD and DO) was performed exploring when and why students choose EM as their specialty. An electronic survey was distributed in March 2015 to all medical students who applied to an EM residency at 4 programs representing different geographical regions. Descriptive analyses and multinomial logistic regressions were performed.793/1372 (58%) responded. Over half had EM experience prior to medical school

2018 PLoS ONE

135. Stenting versus medical therapy for atherosclerotic renal artery stenosis

artery stenosis, defined as greater than 50 per cent reduction in luminal diameter, and hypertension (diastolic blood pressure =95mmHg). The outcomes of interest were blood pressure control, renal function, cardiovascular and renal adverse events (including death), occurrence of restenosis, side effects of medical therapy and use of antihypertensive drugs. The outcomes were reported after a minimum follow up of six months. In the eight included trials, there was a considerable difference (...) to medical therapy on any outcome except the number of antihypertensive drugs used, and the clinical significance of that difference is questionable. However, the authors of both reviews note that limited information about the severity of stenosis and other clinical conditions affecting the patient was available, and investigation of particular subgroups has not occurred to date. The inclusion criteria of a selection of trials, reported in the Cochrane review, give some indication as to the heterogeneity

2016 COAG Health Council - Horizon Scanning Technology Briefs

136. Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses Full Text available with Trip Pro

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses Arthropod-borne flaviviruses are human pathogens of global medical importance, against which no effective small molecule-based antiviral therapy has currently been reported. Arbidol (umifenovir) is a broad-spectrum antiviral compound approved in Russia and China for prophylaxis and treatment of influenza. This compound shows activities against numerous DNA and RNA viruses (...) . The mode of action is based predominantly on impairment of critical steps in virus-cell interactions. Here we demonstrate that arbidol possesses micromolar-level anti-viral effects (EC50 values ranging from 10.57 ± 0.74 to 19.16 ± 0.29 µM) in Vero cells infected with Zika virus, West Nile virus, and tick-borne encephalitis virus, three medically important representatives of the arthropod-borne flaviviruses. Interestingly, no antiviral effects of arbidol are observed in virus infected porcine stable

2018 Viruses

137. Analysis of the drug formulary and the purchasing process at a Moroccan university medical center. (Abstract)

Analysis of the drug formulary and the purchasing process at a Moroccan university medical center. To give an overview of the pharmaceutical policy in the largest medical center in Morocco, a developing country in socio-economic transition.This is an analytical descriptive study of the drug formulary and the purchasing process carried out at the Ibn Sina University Medical Center.Our formulary included 830 drugs belonging to 14 classes according to the Anatomical, Therapeutic and Chemical (ATC (...) ) Classification System. There was a respective predominance of class N (21.8%), class B (13.5%), and class J (12.6%). Injectable route was dominant (46%). Drugs had a significant actual benefit in 70% (according to the French Data), reimbursable in 42.8%, essential in 29.2% according to World Health Organization (WHO) list, and in 36.9% according to the Moroccan list. The calls for tenders included 542 drugs representing 65% of the formulary, and the attribution rate was 71%. The main reason for non

2018 Expert review of pharmacoeconomics & outcomes research

138. Intended and unintended impacts of price changes for drugs and medical services: Evidence from China. (Abstract)

the temporal and cross-sectional variations in the policy implementation and using a unique, nationally representative hospital-level dataset in 1880 counties between 2009 and 2014, we find that the policy change led to a reduction in drug expenditures, a rise in expenditures for medical services, and no measurable changes in total health expenditures. However, we also find an increase in expenditures for diagnostic tests/medical consumables at hospitals that had a greater reliance on drug revenues before (...) Intended and unintended impacts of price changes for drugs and medical services: Evidence from China. In 2012, the Chinese government launched a nationwide reform of county-level public hospitals with the goal of controlling the rapid growth of healthcare expenditure. The key components of the reform were the zero markup drug policy (ZMDP), which removed the previously allowed 15% markup for drug sales at public hospitals, and associated increases in fees for medical services. By exploiting

2018 Social Science & Medicine

139. Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion.

at a 48-hour Interval for Medical Abortion in Young Pregnancy - A Prospective Randomized Controlled Trial. Actual Study Start Date : March 1, 2018 Estimated Primary Completion Date : December 30, 2019 Estimated Study Completion Date : December 30, 2020 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Intervention Administration of drugs concomitantly. Drug: Administration of drugs concomitantly (...) Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion. Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2018 Clinical Trials

140. Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: six-month outcomes of a prospective randomized clinical trial. Full Text available with Trip Pro

Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: six-month outcomes of a prospective randomized clinical trial. To compare the adjunctive clinical effects in the non-surgical treatment of peri-implantitis with either local drug delivery (LDD) or photodynamic therapy (PDT).Forty subjects with initial peri-implantitis, i.e. pocket probing depths (PPD) 4-6 mm with concomitant bleeding on probing (BoP) and marginal bone loss ranging from 0.5 (...) differences (P > 0.05) at baseline, 3 and 6 months with the exception of the mPlI after 6 months.In cases of initial peri-implantitis, non-surgical mechanical debridement with adjunctive use of PDT is equally effective in the reduction of mucosal inflammation as with the adjunctive use of minocycline microspheres up to 6 months. Adjunctive PDT may represent an alternative treatment modality in the non-surgical management of initial peri-implantitis. Complete resolution of inflammation, however

2013 Clinical oral implants research Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>